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Background: A recent Cochrane Review found that preoperative biliary drainage (PBD) in
patients with resectable pancreatic and periampullary cancer undergoing surgery for
obstructive jaundice is associated with similar mortality but increased serious morbidity
compared with no PBD. Despite this clinical evidence of its lack of effectiveness, PBD is still
in use. We considered the economic implications of PBD versus direct surgery for
obstructive jaundice in patients with pancreatic and periampullary cancer.
Materials and methods:Model-based cost-utility analysis estimating mean costs and quality-
adjusted life years (QALYs) per patient from the perspective of the UK National Health
Service over a 6-month time horizon. A decision tree model was constructed and populated
with probabilities, outcomes, and cost data from published sources. One-way and proba-
bilistic sensitivity analyses were undertaken.
Results: PBD was more costly than direct surgery (mean cost per patient £10,775 [$15,616]
versus £8221 [$11,914]) and produced fewer QALYs (mean QALYs per patient 0.337 versus
0.343). Not performing PBD would result in cost savings of approximately £2500 ($3623) per
patient to the National Health Service. PBD had <10% probability of being cost-effective at a
maximum willingness to pay for a QALY of £20,000 ($28,986) to £30,000 ($43,478).
Conclusions: There are significant cost savings to be gained by avoiding routine PBD in
patients with resectable pancreatic and periampullary cancer where PBD is still routinely
used in this context; this economic evidence should be used to support the clinical argu-
ment for a change in practice.
ª 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction option for cure [1e3]. Because obstructive jaundice is thoughtObstructive jaundice is a common symptom in patients with
periampullary cancer (located near the ampulla of Vater) or
cancer of the pancreatic head. Surgical resection is the onlyed Health Research, UCL,
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Elsevier Inc. This is an opeto increase the risk of developing postoperative complica-
tions, preoperative biliary drainage (PBD) was introduced to
improve the postoperative outcome [4]. It has since been
incorporated into the standard surgical treatment algorithm1-19 Torrington Place, London WC1E 7HB, UK. Tel.: þ44 (0)20 7679
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the majority of hospitals [4]. Other factors that may influence
the use of PBD include temporary contraindications for sur-
gery such as severe malnutrition and other comorbidities that
have to be treated before surgery and the interval between
diagnosis and treatment. If there is a long waiting time before
surgery, PBD may have to be performed [1]. However, the
wisdom of delaying surgery in people with an aggressive
cancer such as pancreatic cancer is questionable.
In several studies, PBD reduced morbidity and mortality
after surgery [4e7]. However, a recent Cochrane Review of the
six randomized clinical trials evaluating the safety and
effectiveness of PBD versus no PBD found that PBD in patients
undergoing surgery for obstructive jaundice is associated with
similar mortality but increased serious morbidity compared
with no PBD [8,9]. The review concluded that PBD should not
be used routinely. Nonetheless, there is evidence that PBD is
still commonly used in this context [10] suggesting that clin-
ical considerations alone are not sufficient to change practice.
Consideration of the economic implications of carrying out
routine PBD to health systems may be needed.
A review of the National Health Service (NHS) Economic
Evaluations Database [11] using the search term “biliary
drainage” identified eight studies, but none of these evaluated
PBD versus direct surgery for obstructive jaundice in patients
with pancreatic and periampullary cancer. Therefore, this
study investigates the cost-effectiveness of PBD versus direct
surgery for obstructive jaundice in patients with pancreatic
and periampullary cancer.2. Materials and methods
This is a model-based cost-utility analysis to estimate the
mean cost per patient and the mean outcome per patient
associated with PBD versus direct surgery for obstructive
jaundice in patients with pancreatic and periampullary can-
cer. The outcome measure is quality-adjusted life years
(QALYs), which combine length of life and quality of life [12].
QALYs are the recommended outcome for use in economic
evaluations in the United Kingdom as they are a common unit
that allow for comparable decisions about resource allocation
across different health conditions.
The analysis is undertaken from the perspective of the UK
NHS. Costs are calculated in 2011e2012 UK£with US$ given in
parentheses (UK1 ¼ US$1.449). Since treatment for an acute
condition is being investigated and the Cochrane Review
found that PBD had no impact on mortality, a time horizon of
6mo for costs and outcomeswas considered to be appropriate
and discounting of costs and benefits was unnecessary.
2.1. Model structure
The analysis uses a decision tree to describe the options being
compared and the possible pathways following them (Fig. 1).
This is a commonly used approach in cost-effectiveness
studies of health care programs [12]. The nodes of a decision
tree are points where more than one event is possible. The
branches are mutually exclusive events following each node.
Decision nodes, represented by squares, show the differentoptions thatmight be chosen by decisionmakers based on the
costs and benefits they produce (e.g., to perform PBD or not).
Chance nodes, represented by circles, show uncertain events,
each of which is associated with a probability that it will occur
(e.g., whether or not PBD will have major, mild, or no com-
plications). Terminal nodes, represented by triangles, are the
endpoints of a decision tree, beyond which no further path-
ways are available. Each terminal node has costs and QALYs
associated with it, summarizing the sequence of decisions
and events on a unique path leading from the initial decision
node to that terminal node. These costs and QALYs are ex-
pected values based on the probability of each event on the
pathway occurring up to that point, and the costs and QALYs
associated with each event.
Patients enter the model with potentially resectable peri-
ampullary or pancreatic cancer with malignant obstructive
jaundice. If they undergo PBD, the proceduremay havemajor,
minor, or no complications. In any case, patients may or may
not undergo surgery subsequently because of the complica-
tions of PBD or the underlying cancer, and a proportion of
patients undergoing surgery will be resected. Those who un-
dergo surgery may experience perioperative complications,
and a proportion of those who are resected may require a
repeat laparotomy for recurrence or long-term complications
such as adhesions.
For patients undergoing surgery directly, without PBD, it
was assumed that the treatment pathway is the same as the
one subsequent to PBD, but the probabilities, costs, andQALYs
associated with each pathway may be different.
2.2. Probabilities
The probabilities associatedwithmutually exclusive events at
each chance node were obtained from published sources
(Tables 1 and 2) [13e18]. Additional data were extracted from
the six randomized clinical trials included in the Cochrane
Review on the probability of major and minor complications
related to PBD and to surgery. The probabilities for patients in
each group undergoing surgery, being resected if they did
undergo surgery, and requiring a repeat laparotomy if they
were resected were taken from a single large trial included in
the Cochrane Review [17].
2.3. Outcomes
The quality of life component of QALYs is measured by utility
scores. A utility score of 1 represents full health and a utility of
0 death; negative values represent states worse than death. A
review of utility weights in the cost-effectiveness analysis reg-
istry [11] was undertaken using the search terms “pancreas,”
“pancreatic,” “ampullary,” and“periampullary.”After reviewing
the reference lists of the identified studies and removing du-
plicates, five studies containing potentially relevant utility data
were identified [19e23]. The utility scores used in the model
were from one study [22], selected because values were pre-
sented for different points over time andutility scores for all the
health states in the model were included, thus enabling better
comparability between values, and the values reported also re-
flected trends in disease-specific quality of life measures found
in other studies (Table 2) [24e26]. Utility scores were measured
Fig. 1 e Decision tree model structure.
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pezium rule for calculating theareaunder a curve. Because they
did not measure directly the utility among patients undergoing
PBD versus direct surgery for obstructive jaundice in patients
with pancreatic and periampullary cancer, the utility scores
were judged to be weak and so were tested comprehensively in
sensitivity analyses.2.4. Costs
The costs of PBD with major, minor, and no complications
were assumed to be £4036, £2846, and £2897($5849, $4125, and
$4199), respectively (Table 2), based on national mean costs of












Hatfield et al. [13] 29 NA
Lai et al. [14] 43 NA 1
McPherson et al. [15] 34 NA
Pitt et al. [16] 37 NA
van der Gaag et al. [17] 102 20 2
Wig et al. [18] 20 2
Total 265 22 5
NA ¼ data not available.pancreatic procedures provided on an elective inpatient basis
[27]. Surgical resection with and without complications was
assumed to cost £9209 ($13,346) and £7711 ($11,175), respec-
tively [27]. Patients who undergo surgery but are not resected
receive palliative surgery and this was assumed to cost £5378
($7794) with complications and £4487 ($6503) without com-
plications [27]. Patients who do not undergo surgery receive
palliative treatment only, at an assumed cost of £4487 ($6503)
[26]. The cost of repeat laparotomy in those who underwent
surgical resection was assumed to be £7711 ($11,175) [27].
2.5. Measuring cost-effectiveness
Cost-effectiveness wasmeasured usingmonetary net benefits













4 4 28 4
2 16 44 18
8 9 31 13
4 16 38 20
7 48 94 35
4 5 20 11
9 98 255 101
Table 2 e Model parameters for decision tree model and range of values used in univariate sensitivity analysis.
Base case value Distribution Alpha Beta Sources Range
Probabilities
PBD
Pr(major complications with PBD) 0.223 Dirichlet (59) [13e18] 0e1
Pr(minor complications with PBD) 0.083 Dirichlet (22) [13e18] 0e1
Pr(no complications with PBD) 0.694 Dirichlet (184) [13e18] 0e1
Pr(undergoes surgery) 0.931 Beta 95 7 [17] 0e1
Pr(resected) 0.600 Beta 57 38 [17] 0e1
Pr(complications if resected) 0.370 Beta 98 167 [13e18] 0e1
Pr(complications if not resected) 0.370 Beta 98 167 [13e18] 0e1
Pr(repeat laparotomy) 0.211 Beta 12 45 [17] 0e1
Direct surgery 0e1
Pr(undergoes surgery) 0.979 Beta 92 2 [17] 0e1
Pr(resected) 0.685 Beta 63 29 [17] 0e1
Pr(complications if resected) 0.396 Beta 101 154 [13e18] 0e1
Pr(complications if not resected) 0.396 Beta 101 154 [13e18] 0e1
Pr(repeat laparotomy) 0.206 Beta 13 50 [17] 0e1
Unit costs
PBD with major complications 4036 (5849) Gamma 1 4036 [27] 2000e6500
PBD with minor complications 2846 (4125) Gamma 1 2846 [27] 1700e3300
PBD without complications 2897 (4199) Gamma 1 2897 [27] 1000e4000
Resection with complications 9209 (13,346) Gamma 1 9209 [27] 6000e11,000
Resection without complications 7711 (11,175) Gamma 1 7711 [27] 5000e10,000
Palliative surgery with complications 5378 (7794) Gamma 1 5378 [27] 3500e6500
Palliative surgery without complications 4487 (6503) Gamma 1 4487 [27] 2000e6000
Do not undergo surgery (palliative treatment only) 4487 (6503) Gamma 1 4487 [27] 2000e6000
Repeat laparotomy 7711 (11,175) Gamma 1 7711 [27] 5000e10,000
Utilities
PBD with complications, undergoes surgery, resected, no complications
6 wk 0.54 Beta 52.38 44.62 [22] 0e1
3 mo 0.74 Beta 71.78 25.22 [22] 0e1
6 mo 0.80 Beta 77.60 19.40 [22] 0e1
PBD with complications, undergoes surgery, resected, with complications
6 wk 0.54 Beta 52.38 44.62 [22] 0e1
3 mo 0.71 Beta 68.87 28.13 [22] 0e1
6 mo 0.78 Beta 75.66 21.34 [22] 0e1
PBD with complications, undergoes surgery, not resected
6 wk 0.54 Beta 52.38 44.62 [22] 0e1
3 mo 0.67 Beta 64.99 32.01 [22] 0e1
6 mo 0.72 Beta 69.84 27.16 [22] 0e1
PBD with complications, does not undergo surgery
6 wk 0.54 Beta 52.38 44.62 [22] 0e1
3 mo 0.72 Beta 69.84 27.16 [22] 0e1
6 mo 0.72 Beta 69.84 27.16 [22] 0e1
PBD no complications, undergoes surgery, resected, no complications
2 wk 0.60 Beta 58.20 38.80 [22] 0e1
3 mo 0.74 Beta 71.78 25.22 [22] 0e1
6 mo 0.80 Beta 77.60 19.40 [22] 0e1
PBD no complications, undergoes surgery, resected, with complications
2 wk 0.60 Beta 58.20 38.80 [22] 0e1
3 mo 0.71 Beta 68.87 28.13 [22] 0e1
6 mo 0.78 Beta 75.66 21.34 [22] 0e1
PBD no complications, undergoes surgery, not resected
2 wk 0.60 Beta 58.20 38.80 [22] 0e1
3 mo 0.67 Beta 64.99 32.01 [22] 0e1
6 mo 0.72 Beta 69.84 27.16 [22] 0e1
PBD no complications, does not undergo surgery
2 wk 0.60 Beta 58.20 38.80 [22] 0e1
3 mo 0.72 Beta 69.84 27.16 [22] 0e1
6 mo 0.72 Beta 69.84 27.16 [22] 0e1
Direct surgery, undergoes surgery, resected, no complications
2 wk 0.60 Beta 58.20 38.80 [22] 0e1
3 mo 0.74 Beta 71.78 25.22 [22] 0e1
6 mo 0.80 Beta 77.60 19.40 [22] 0e1
(Continued on next page)
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Table 2 e (Continued )
Base case value Distribution Alpha Beta Sources Range
Direct surgery, undergoes surgery, resected, with complications
2 wk 0.57 Beta 55.29 41.71 [22] 0e1
3 mo 0.71 Beta 68.87 28.13 [22] 0e1
6 mo 0.78 Beta 75.66 21.34 [22] 0e1
Direct surgery, undergoes surgery, not resected
2 wk 0.54 Beta 52.38 44.62 [22] 0e1
3 mo 0.67 Beta 64.99 32.01 [22] 0e1
6 mo 0.72 Beta 69.84 27.16 [22] 0e1
Direct surgery, does not undergo surgery
2 wk 0.76 Beta 73.72 23.28 [22] 0e1
3 mo 0.72 Beta 69.84 27.16 [22] 0e1
6 mo 0.72 Beta 69.84 27.16 [22] 0e1
Unit costs are in 2011e2012 UK£ (US$). The base case values are used to produce the deterministic results. The distributions are used to un-
dertake the probabilistic sensitivity analysis, to produce the probabilistic results, and construct the cost-effectiveness acceptability curves.
j o u r n a l o f s u r g i c a l r e s e a r c h 1 9 3 ( 2 0 1 5 ) 2 0 2e2 0 9206meanQALYs per patient accruing to that treatmentmultiplied
by decision makers’ maximum willingness to pay for a QALY
(also referred to as the cost-effectiveness threshold, which in
the United Kingdom is approximately £20,000 [$28,986] to
£30,000 [$43,478] per QALY gained) [28], minus the mean cost
per patient for the treatment. This approach converts the
outcomes from each treatment into monetary terms and then
subtracts the costs of each treatment from the monetized
benefits, calculating the net benefit of each treatment in
monetary terms. MNBs were calculated using the base case
parameter values shown in Table 2; these are referred to as
deterministic results because they do not depend on chance.
The treatmentwith the highestMNB represents the best value
for money and is preferred on cost-effectiveness grounds.2.6. Sensitivity analyses
One-way sensitivity analysis was undertaken, varying the
probabilities, outcomes, and costs one at a time within the
ranges listed in Table 2. The aim was to identify the threshold
value for each parameter, where one exists, where the treat-
ment with the highest MNB changed (e.g., the value at which
PBD was the most cost-effective option). An analysis was also
undertaken that based on the probabilities of complicationsTable 3 e Base case results.
PBD
Costs
UK£ 10,775 (10,502 to 11,
US$ 15,616 (15,220 to 16,
QALYs 0.337 (0.337 to 0.33
MNB
UK£20,000 4031 (3758 to 43
US$28 986 5843 (6485 to 56
UK£30,000 659 (386 to 933
US$43 478 956 (1599 to e79
Costs are in 2011e2012 UK£ and US$. Figures are expected values per patie
base case values of the model parameters (deterministic results). The 95%
simulations in the probabilistic sensitivity analysis. The MNB is calculated
£30,000 ($43 478). Numbers may not sum because of rounding.withPBDandwithcomplicationsofsurgeryonasingle largetrial
[17] rather than all six studies included in the Cochrane Review.
A probabilistic sensitivity analysis (PSA) was undertaken, as
recommended by the National Institute for Health and Care
Excellence (NICE) [28]. Distributions were assigned to parame-
ters (Table 2) to reflect the uncertainty with each parameter
value. A random value from the corresponding distribution for
each parameterwas selected. This generated an estimate of the
mean cost andmean QALYs and theMNB associated with each
treatment. This was repeated 5000 times, and the results for
each simulationwere noted. Themean costs, QALYs, andMNBs
for each treatment were calculated from the 5000 simulations;
thesearereferredtoasprobabilistic resultsbecausetheydepend
onchance. Using theMNBs for each of the 5000 simulations, the
proportion of times each treatment had the highest MNB was
calculated for a range of values for themaximumwillingness to
pay for aQALY. Thesewere summarized graphically using cost-
effectiveness acceptability curves [12].
In the PSA, we used beta and Dirichlet distributions to
model uncertainty in the probabilities, beta distributions to
model uncertainty in utility scores, and gamma distributions
to model uncertainty in costs (Table 2) [29]. Dirichlet distri-
butions were fitted using Excel macros developed by the
Centre for Bayesian Statistics in Health Economics at the
University of Sheffield [30]. In cases where standard errorsDirect surgery
048) 8221 (7954 to 8487)
012) 11,914 (11,528 to 12, 300)
8) 0.343 (0.343 to 0.344)
04) 1359 (1092 to 1626)
85) 1969 (2551 to e1768)
) 2072 (1805 to 2340)
8) 3003 (2424 to 3206)
nt with 95% CIs in brackets. The point estimates are calculated using
CIs are derived using standard deviations calculated from the 5000
at a maximumwillingness to pay for a QALY of £20,000 ($28 986) and
Fig. 2 e Cost-effectiveness acceptability curves showing the probability that each option is cost-effective at different values
of the maximum willingness to pay for a QALY. In the United Kingdom, the lower and upper limit of the maximum
willingness to pay for a QALY are £20,000 ($28 986) and £30,000 ($43 478), respectively.
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sources used, it was assumed the standard error was equal to
the mean [29]. For the utilities, the variance was calculated
assuming a beta distribution based on 97 observations [22,23].
Parameter values used to characterize each distribution are in
Table 2. For each of the base case values, 95% confidence in-
tervals (CIs) were derived using standard deviations calcu-
lated from the 5000 simulations in the PSA.3. Results
Using base case values, PBD for obstructive jaundice in patients
with pancreatic and periampullary cancer was more costly
than direct surgery, with a mean cost per patient £10,775 (95%,
CI £10,502 to £11,048, $15 616, 95% CI, $15 220 to $16 012) versus
£8221 (95%CI, £7954 to £8487, $11 914, 95%CI, $11528 to $12 300);
a significant cost increase of £2554 ($3701) per patient
compared with direct surgery (Table 3). The increase in costs
was due to the additional cost of the PBD procedure. QALYs up
to 6 mo were slightly lower for PBD compared with direct sur-
gery (0.337 [95% CI, 0.337e0.338] versus 0.343 [95% CI,
0.343e0.344]), because of the complications associated with
PBD. The MNBs for PBD were significantly lower than those for
direct surgery at maximum willingness to pay for a QALY of
£20,000 ($28,986) and £30,000 ($43,478), indicating that direct
surgery was preferred on cost-effectiveness grounds. As ex-
pected, the probabilistic results were numerically similar to the
deterministic results (not shown).
In the one-way sensitivity analysis (Table 2), the results
were neither sensitive to changing the values of the parame-
ters within the ranges stated nor were they sensitive to basingthe probabilities of complications with PBD and with compli-
cations of surgery on a single large trial [17]: in every situation
direct surgery was the most cost-effective option.
The cost-effectiveness acceptability curves for each treat-
ment show that PBD had a 9.5% probability of being cost-
effective at a maximum willingness to pay for a QALY of
£20,000 ($28,986) and a 8.9% probability at a value of £30,000
($43,478; Fig. 2).4. Discussion
4.1. Main findings
This study estimated the expected cost and QALYs of PBD
versus direct surgery for obstructive jaundice in patients with
pancreatic and periampullary cancer. Routine use of PBD was
not cost-effective. It wasmore costly than direct surgery, with
a mean cost per patient £10,775 ($15,616) versus £8221
($11,914), respectively. It also produced fewer QALYs, with
mean QALYs per patient of 0.337 versus 0.343, respectively.
The MNB for PBD was lower than for direct surgery at a
maximum willingness to pay for a QALY of £20,000 ($28,986)
and £30,000 ($43,478). There is little uncertainty with this
finding, demonstrated through extensive one-way and prob-
abilistic sensitivity analyses.4.2. Strengths and weaknesses
The strengths of this study are that it was based on a recently
published Cochrane Review that analyzed in detail the
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to patients with obstructive jaundice [8,9]. A comprehensive
sensitivity analysis has also been performed, showing that
although there is some uncertainty in the values used in the
base case analysis, the conclusions are not sensitive to
changing these values.
There are a number of weaknesses. First, the utility scores
on which the QALY estimates were made are weak. However,
the results are not sensitive to the values used, as demon-
strated in sensitivity analyses. Second, the time horizon of the
model over which costs and QALYs are measured is 6 mo. We
have ignored differences in costs and QALYs beyond 6 mo. It
may be that some of the complications of PBD persist beyond
6 mo, and if so including costs and outcomes beyond 6 mo
would favor direct surgery. Third, the analysis was under-
taken from the perspective of the UK NHS. A wider perspec-
tive, for example, a societal one, would also include impacts
on the rest of society, including patients, families, and busi-
nesses. Given that PBD is associated with additional morbidity
and also involvesmanaging a drain during the period of PBD, it
may be that if the costs from these other viewpoints were
included, the cost increases attributable to PBD would be
greater than shown.
4.3. Comparison with other studies
This is the first study to evaluate the cost-effectiveness of PBD
for obstructive jaundice in pancreatic and periampullary
cancer. The data on which this cost-effectiveness analysis
was based were from a systematic review, which appraised
the existing literature in depth [8,9].
4.4. Implications for policy and practice
This study provides a strong economic case to support the
clinical evidence that PBD for obstructive jaundice in patients
with pancreatic and periampullary cancer should not be used
routinely. The findings are equally applicable in patients with
distal cholangiocarcinomas and duodenal tumors with
obstructive jaundice. This is because although the majority of
tumors included in the trials, which provided the data for this
cost-effectiveness analysis had pancreatic or ampullary tu-
mors, the underlying reason for performing a PBD is the same
in distal cholangiocarcinomas and duodenal tumors. These
findings are applicable only in patients eligible for surgical
resection with obstructive jaundice. Only about 20% of pa-
tients with pancreatic and periampullary cancer are eligible
for surgical resection [1]. The findings are also not applicable
in patients with cholangitis because of the common bile duct
obstruction or in patients undergoing preoperative neo-
adjuvant chemotherapy. The mean duration of jaundice was
stated in three trials and ranged between 28 and 55 d. So, the
findings of this review are only applicable when the interval
between jaundice and surgery is <2 mo on average [4,15,18].
However, our cost-effectiveness analysis provides a sound
basis for avoiding excessive delays to surgery because of
administrative reasons.
There is no evidence on the extent of use of PBD for
obstructive jaundice in patients with pancreatic and peri-
ampullary cancer in the United Kingdom, so a national budgetimpact calculation is not possible. However, based on the
findings in the present study, not performing PBD in patients
with pancreatic and periampullary cancer would result in cost
savings of approximately £2500 ($3623) per patient to the NHS.
4.5. Further research
This study is based on a Cochrane Review of PBD for
obstructive jaundice. However, this analysis considered only
the cost-effectiveness of PBD use in patients with resectable
pancreatic and periampullary cancer who had been consid-
ered suitable for inclusion in trials comparing drainage with
no drainage before surgery. Further economic evaluation is
required to assess the costs and benefits in patients who were
excluded from the trials such as those with cholangitis, high
bilirubin levels (>250 mL/L), associated renal failure, or those
undergoing preoperative neoadjuvant chemotherapy.
The Cochrane Review concluded that further randomized
controlled trials, with low risk of bias, including long-term
survival and quality of life measures are needed in patients
with malignant obstructive jaundice. Such trials should also
collect utility and cost data to facilitate cost-effectiveness
analyses.5. Conclusions
Routine PBD for obstructive jaundice in patients with
pancreatic and periampullary cancer is not cost-effective.
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